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Abstract: Polyethyleneimine, poly-L-lysine, chitosan and some others cationic polymers have been
thoroughly studied as nucleic acid delivery systems in gene therapy. However, the drug release from
these systems proceeds at a very low rate due to extremely high binding between a carrier and gene
material. To reduce these interactions and to enhance drug release, we developed a set of amphiphilic
polypeptides containing positively and negatively charged amino acids as well as a hydrophobic one.
The copolymers obtained were characterized by size-exclusion chromatography, static light scattering,
HPLC amino acid analysis and 1HNMR spectroscopy. All copolymers formed particles due to a
self-assembly in aqueous media. Depending on polypeptide composition, the formation of particles
with hydrodynamic diameters from 180 to 900 nm was observed. Stability of polymer particles,
loading and release efficiency were carefully studied. Cellular uptake of the particles was efficient and
their cytotoxicity was negligible. The application of polymer carriers, containing siRNA, to vascular
endothelial growth factor (VEGF-A165) silencing of ARPE-19 cells was successful. The gene silencing
was confirmed by suppression of both messenger RNA and protein expression.
Keywords: amphiphilic polypeptides; self-assembly; nanoparticles; siRNA delivery; VEGF; gene silencing
1. Introduction
Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are among the most
common ocular diseases that lead to the impairment or loss of vision [1,2]. Proliferative neovascular
forms of DR and AMD are characterized by the formation of new vessels from the existing ones,
because the proliferation and migration of endothelial cells are stimulated by over-expression of vascular
endothelial growth factor (VEGF) [3]. Inhibition of VEGF via intraocular injections of anti-VEGF drugs
are the corner-stone approach in the treatment of AMD and diabetic macular edema that is associated
with DR. Currently, a common clinical therapy is based on application of the monoclonal antibodies
(mABs) that specifically bind to VEGF, and neutralize its function. Such recombinant monoclonal
antibodies as bevacizumab and its Fab-fragment ranibizumab bind with high affinity to the site present
in all VEGF isoforms [4,5]. Besides antibodies, there is also the aptamer pegaptanib (28-nucleotide RNA
aptamer) that was registered for the treatment of neovascular AMD fifteen years ago [4,5]. In spite
of the existing clinical therapeutics, some drawbacks still exist in the treatment of neovascular AMD.
Monthly or bimonthly injections into the vitreous of the eye constitute a major burden to the patients
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and healthcare. Furthermore, the intravitreal injections may lead to some complications, such as retinal
detachment, intraocular pressure increase, ocular infection, and hyperemia.
In contrast to the mABs and aptamers, small-interfering RNAs (siRNAs) do not block protein
function but play a key role in the post-transcriptional gene silencing [6]. siRNAs have a great potential
as drugs, including the treatment of ocular diseases. For instance, phase II clinical trials of ocular
siRNA treatments were reported [7]. These trials by the Quark and Pfizer companies aim at developing
treatments for wet AMD, glaucoma and some other ocular diseases.
To inhibit intracellular VEGF synthesis, usually picomole quantities of siRNA are necessary [8].
Moreover, siRNAs provide a long therapeutic effect with a single administration and thereby may
reduce the risks and burden associated with intravitreal anti-VEGF therapy. Another benefit of
siRNA is the simple synthesis and possibility to up-scale the production. However, the successful
application of siRNAs is limited by the necessity to overcome several biological barriers [9]. The first
one is the penetration across the cell membrane. The physicochemical properties of siRNAs, such as
hydrophilicity, relatively large size and net negative charge, complicate their entrance to the cell.
After cellular internalization, siRNA must escape the endosomes and reach the cytosol, where it must
be involved into formation of the RNA-inducing silencing protein complex (RISC) and recognize
the target mRNA. Furthermore, siRNA is subject to enzymatic degradation, but its stability can be
improved with chemical modifications (e.g., phosphorothioate) and formulation techniques.
To overcome the obstacles, different siRNA delivery systems have been investigated. The carriers
for siRNA delivery should meet some requirements. They must be biocompatible, biodegradable
and they must have suitable combination of chemical-physical properties, including charge, size,
stability, and possibility to surface functionalization. Currently, the encapsulation of the siRNAs into
nanoparticles is based on lipids [10,11] or polymers [12,13], or their complexation with cell-penetrating
peptides [14,15] or cationic-polymers [16–19]. Such technologies have been summarized in some recent
reviews [20,21]. Self-assembled into micelles or liposomes, the cationic lipids can entrap siRNA and
facilitate its cellular entry by endocytosis. However, a poor stability of such systems has induced a
wave of studies on their covalent and non-covalent modification with PEG or its copolymers [22,23].
The preparation of complex delivery systems, for example, consisting of siRNA-cationic lipid complex
encapsulated into folate-PEG-co-(polylactic acid-co-polyglycolic acid)-polyketal nanoparticles [12] or
based on poly(ε-caprolactone)-co-PEG-co-poly(l-histidine) [13] were recently reported.
Protonable cationic polymers are among the leading candidates for nucleic acid binding and
intracellular delivery. They are characterized with high buffering capacity at endosomal pH range (about
5.5–7.4) and it is hypothesized that they can mediate endosomal escape by acting as ‘proton sponges’.
Polyethyleneimine (PEI), poly-L-lysine, chitosan and its derivatives are the most widely studied cationic
polymers for nucleic acid delivery [17,19,24]. Despite high binding and cellular transfection efficiency of
many polymers, they are not biodegradable (e.g., PEI, chitosan) or form stable polyplexes with limited
release of nucleic acids (e.g., poly-L-lysine). To facilitate the release of nucleic acid from polyplex,
recently, Pilipenko et al. suggested the introduction of heparin as concurrent polyanion to chitosan [25].
Chitosan-heparin polyplexes with different ratios of positive and negative polysaccharides were
prepared and their efficiency for delivery of DNA and siRNA into human keratinocytes was estimated.
Following that idea, in present work, we developed a set of random amphiphilic polypeptides
consisting of positively and negatively charged amino acids as well as a hydrophobic one. L-Lysine
and L-glutamic acid were selected as oppositely charged amino acids to control siRNA binding and
release. L-Phenylalanine or L-isoleucine provided polypeptide self-assembly and possibly facilitated
delivery of siRNA across the cell membrane. The ratio between the three amino acids was varied to
find the composition of polypeptides that provides optimal particle size, zeta potential, encapsulation
efficiency, cytotoxicity and VEGF-A165 silencing in retinal pigment epithelial cells.
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2. Materials and Methods
2.1. Materials
ε-Z-L-Lysine, γ-benzyl-L-glutamate, L-phenylalanine, L-isoleucine, triphosgene, α-pinene,
trifluoroacetic acid (TFA), trifluoromethanesulfonic acid (TFMSA), and other reagents for NCA and
polymer synthesis were ordered in Sigma-Aldrich (Darmstadt, Germany). All organic solvents,
i.e., N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) 1,4-dioxane, petroleum ether,
ethyl acetate, and some others were purchased from Vecton Ltd. (St. Petersburg, Russia), and purified
before use. The buffer solutions were prepared by dissolving salts of ACS reagent grade purchased
from Vecton Ltd. (St. Petersburg, Russia) in deionized water and afterwards the solutions were filtered
through a 0.45-µm membrane Milex, Millipore Merck (Darmstadt, Germany). For purification of
synthesized polymers, Spectra/Pore® dialysis bags (MWCO: 1000, Rancho Dominguez, CA, USA)
were used. Filter tubes (30,000) were ordered in Merck and in Sartorius (Göttingen, Germany).
SEC column calibration was performed with the use of poly(methyl methacrylate) (PMMA)
standards (Mw = 17,000–250,000;Đ ≤ 1.14) purchased from Supelco (Bellefonte, PA, USA). Poly-L-lysine
(Mw = 15,000–30,000) was a product of Sigma-Aldrich.
Model non-labeled and Cy3-labeled 23-base pairs duplex of oligothymidine and oligoadenine
(oligo-dT-dA) were purchased from BiobeagleTM (St. Petersburg, Russia). Dulbecco’s modified Eagle’s
medium (DMEM), penicillin, streptomycin and fetal bovine serum (FBS) were obtained from BioloT
(St. Petersburg, Russia).
The 27-base pairs (bp) double stranded RNA were selected as target to VEGF-A165 gene.
siRNA sequence was the following: Sense—5′-CUUCCUACAGCACAACAAAUGUGAAUG-3′,
antisense: 3′-GAAGGAUGUCGUGUUGUUUACACUUAC-5′. The same siRNA labelled with Cy5
was utilized for the visualization experiments. Cy5-labeled and non-labeled 27-bp VEGF siRNAs and
scrambled 27-bp RNA for control (siControl) (sense 5′-GUAAGUGUAAACAACACGACAUCCUUC-3′,
antisense: 3′-CAUUCACAUUUGUUGUGCUGUAGGAAG-5′ [21] were purchased from GenTerra
(Moscow, Russia). The primers used for the target mRNA: VEGF forward and reverse primers, GAPDH
forward and reverse primers were obtained from GenTerra.
Human retinal pigment epithelial (ARPE-19) cell line was a product of American Type Culture
Collection (ATCC, Manassas, VA, USA), while HEK-293 (human embryonic kidney) and BEAS-2B
(human bronchial epithelium) cell lines were obtained from the German Collection of Microorganisms
and Cell Culture (DSMZ, Braunschweig, Germany).
2.2. Methods
2.2.1. Synthesis and Characterization of Polypeptides
Polypeptides were synthesized by ring-opening polymerization (ROP) of α-amino acid
N-carboxyanhydrides (NCA) as random structures. NCA monomers of Lys(Z), Glu(OBzl), Phe and
Ile were prepared as described elsewhere [26]. In all cases, anhydrous dioxane was used as a solvent.
Acquired NCAs were purified by recrystallization twice from anhydrous ethyl acetate/n-hexane.
Yields: Lys(Z) NCA—87%, Glu(OBzl) NCA—89%, Phe NCA—74%, Ile NCA—69%.
The structure and purity of NCAs were testified by 1H-NMR at 25 ◦C in CDCl3. The spectra were
recorded using a 400 MHz Avance instrument (Bruker, Karlsruhe, Germany). Lys(Z) NCA: δ 7.43–7.28
(m, 5H), 6.97 (s, 1H), 5.12 (s, 2H), 4.97 (s, 1H), 4.32–4.23 (t, J = 5.2, 1H) (s, 1H), 3.29–3.14 (m, 2H),
2.03–1.90 (m, 1H), 1.90–1.75 (m, 1H), 1.73–1.28 (m, 4H); Glu(OBzl) NCA: 2.05–2.39 (m, 2H), 2.63 (t, 2H),
4.39 (t, 1H), 5.17 (s, 2H), 6.40 (br. s., 1H), 7.39 (m, 5H); Phe NCA: 2.94–3.35 (m, 2H), 4.55 (m, 1H), 6.12
(s, 1H), 7.19–7.41 (m, 5H); Ile NCA: 0.836 (t, 3H), 0.871 (d, 3H), 1.236 (dq, 2H), 1.941 (qtd, 1H), 4.28
(d, 1H).
Two series of polypeptides, e.g., P(Lys(Z)-co-Glu(OBzl)-co-Phe) and P(Lys(Z)-co-Glu(OBzl)-co-Ile),
were synthesized using n-hexylamine as initiator. The NCA/initiator molar ratio was 100. The following
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initial ratio of NKAs were used for the synthesis: (1) Lys(Z)/Glu(OBzl)/Phe = 60/20/20 (KEF1), 40/40/20
(KEF2) and 20/60/20 (KEF3); (2) Lys(Z)/Glu(OBzl)/Ile = 60/10/30 (KEI1), 50/20/30 (KEI2) and 40/30/30
(KEI3). The polymerization was performed in anhydrous 1,4-dioxane, preparing 4 wt% solution of
NCAs. Then α-pinene and triphosgene were added. The reaction was carried out at 55 ◦C over 4 h.
The product was precipitated with an excess of diethyl ether, then the precipitate was filtrated, washed
with diethyl ether and then dried.
Molecular-weight characteristics (weight average and number average molecular weights, Mw
and Mn, respectively, as well as dispersity, Đ) of polymers were evaluated by SEC. Shimadzu
LC-20 Prominence system supplied with refractometric RID 10-A detector (Kyoto, Japan) and
7.5 mm × 300 mm Agilent PLgel MIXED-D column (Chrom Tech, Apple Valley, MN, USA) were
applied for SEC analysis. DMF with 0.1 M LiBr was used as a mobile phase. The analysis was
performed at 40 ◦C under 1.0 mL/min of the mobile phase flow rate. SEC LC Solutions software
(Shimadzu, Kyoto, Japan) was used for calculations of Mw, Mn andĐ regarding to the calibration curve
plotted for PMMA standards.
Additionally, the molecular weights and hydrodynamic radius Rh–D for macromolecules
were measured by static and dynamic light scattering methods in solutions in DMSO at 21.0 ◦C.
Light scattering was studied on a Photocor Complex unit (Photocor Instruments, Moscow, Russia);
a Photocor-DL diode laser served as a light source (power of 5–30 mW, wavelength λ = 659.1 nm).
The unit was calibrated by benzene (RV = 2.32 × 10−5 cm−1). The correlation function of the scattered
light intensity was obtained with the use of a Photocor-PC2 correlator with 288 channels and was
processed with DynalS software. In these solutions, the asymmetry of light scattering was absent;
thus, Mw of copolymers was determined by the Debay method. The refractive index increments were
measured on a Refractometer RA-620 (KEM, Kyoto, Japan).
The Bzl- and Z-protective groups were removed by TFMSA/TFA mixture at a ratio 1/10 using
known procedure [27]. After deprotection, the product was dissolved in DMF, placed into a dialysis
bag (MWCO 1000), and dialyzed against water for 36 h.
The amino acid compositions of the polymers were determined using HPLC amino acid analysis
after total hydrolysis of polypeptides up to free amino acids. The hydrolysis of 1 mg of a polypeptide
dissolved in 1 mL of 6 M HCl with 0.0001% phenol was carried out in a sealed ampoule for 48 h at 110
◦C. The solvent was evaporated several times with water to eliminate HCl and to reach neutral pH.
The hydrolysates were analyzed using LC-20 Shimadzu system with refractometric RID-20A detector
(all from Shimadzu, Kyoto, Japan) equipped with 4.6 × 125 mm Shodex IC YS-50 column, 5 µm beads
(Showa Denko, Kyoto, Japan). The isocratic elution mode was applied and 3 mM H3PO4 solution was
used as eluent. The mobile phase flow rate was 1.0 mL/min.
2.2.2. Preparation and Characterization of Polypeptide Particles
Polymer nanoparticles were obtained by phase inversion during dialysis from DMSO to water
followed by freeze drying for 2 days and finally dispersing for 30 s under sonication using 10% power
of ultrasonic homogenizer (Bandelin Sonopuls HD2070, Berlin, Germany) at necessary concentration
(0.20–1.50 mg/mL) in water or buffer of choice.
Average hydrodynamic diameter of particles (DH) and polydispersity index (PDI) were established
at 25 ◦C by dynamic light scattering (DLS) Zetasizer Nano ZS equipped with a He–Ne laser beam at
λ = 633 nm and a scattering angle of 173◦ (Malvern Instruments, Worcester, UK). DLS experiments were
performed in deionized water, DMEM and PBS, pH 7.4, whereas the zeta-potentials were determined
in deionized water. To study the pH effect, ζ-potential was measured in deonized water containing
10−3 M NaCl and adjusted with 0.1 M HCl/NaOH to pH 3–12.
The morphology was investigated by transmission electronic microscopy (TEM) using a JEM-2100
microscope (Jeol, Tokyo, Japan) operated at an acceleration voltage of 160 kV. The samples were
prepared by dropping 3 µL of particles’ suspension (0.3 mg/mL) on copper grid covered with carbon
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and further staining with 3 w/w% uranyl acetate solution for 1 min. The grids were washed gently
with pure water and dried for 30 min before the measurement.
Critical micelle concentration (CMC) was determined by conductometry. The measurements
of conductivity were performed at 25 ◦C in the range of concentrations 0.5–35 µg/mL with the
use of SevenCompact Cond meter S230 conductometer (Mettler Toledo, Columbus, OH, USA).
CMC was determined as the intersection point of two linear sections of the conductivity vs. polymer
concentration plots.
2.2.3. Encapsulation and Release of RNA, Duplex Oligo-dT-dA and siRNA
Due to the presence of ε-amino groups of lysine in polypeptides obtained, negative oligo- and
polynucleotides can easily bind to them due to the ionic interactions. Firstly, the suspension of
polypeptide particles with concentration of 1 mg/mL was prepared and then diluted to a desired
concentration. Then, the solution of oligonucleotide (0.1 nmol/µL) or siRNA (0.05 nmol/µL) was added
quickly to suspension under stirring (Vortex, Thermo Fischer Scientific, Vantaa, Finland).
To determine the loading efficiency of polypeptide nanoparticles regarding to oligonucleotides
we used Cy3-oligo-dT-dA. After encapsulation, non-bound Cy3-oligo-dT-dA was separated from
nanoparticles by centrifugation (10,000× g) at 4 ◦C for 20 min in Amicon Ultra filter tubes with MWCO
30,000 (Merck). The filtrate containing free Cy3-oligo-dT-dA was collected and then analyzed using a
Thermo Scientific Varioscan microplate reader at excitation and emission wavelengths of 550 and 570
nm, respectively. The amount of free Cy3-oligo-dT-dA was determined using a linear calibration plot
and then the amount of loaded Cy3-oligo-dT-dA was calculated as a difference between initial and
non-bound oligonucleotide amounts. The entrapment efficacy (EE) was calculated using the following
equation:
EE = (m1−m2)/m1 × 100% (1)
where m1 is initial amount of Cy3-oligo-dT-dA, but m2 is the amount of non-bound Cy3-oligo-dT-dA.
In vitro release of Cy3-oligo-dT-dA from nanoparticles was investigated over 5 days. 100 µL of
test formulation was diluted with 300 µL of the release medium (0.01 M Na-phosphate buffer, pH
7.4, cell culture medium DMEM or DMEM-F12 with 10% (v/v) fetal calf serum, FCS) and placed in
Eppendorf filter tubes, which were incubated in a thermoshaker at 37 ◦C and stirring for 300 rpm.
After a certain period, the tubes were centrifuged at 10,000× g for 10 min. The filtrates that contained
free Cy3-oligo-dT-dA were collected and fluorescence of Cy3 was analyzed using a fluorometer (λex
= 550 nm, λem = 570 nm). The amount of free Cy3-oligo-dT-dA was calculated using a linear
calibration plot.
2.2.4. Cytotoxicity of Particles
ARPE-19, HEK-293 and BEAS-2B were used for cytotoxicity evaluation. 104 cells per well were
cultured in a 96-well plate (200 µL/well) in DMEM-F12 containing 10% (v/v) fetal calf serum and 1% (v/v)
penicillin/streptomycin (72 h, 37 ◦C, a humidified atmosphere of 5% CO2). After that, the cells were
cultivated in the culture medium containing test empty polypeptide particles at the concentrations from
3 to 125 µg/mL for 24 and 72 h. The viability was evaluated using MTT-assay. For that, culture medium
was aspirated and 100 µL/well of MTT solution (1.0 mg/mL in DMEM-F12) was added. The plate
was incubated for 2 h. Finally, the solution was removed and 100 µL of DMSO was added to each
well. After 10 min of gentle shaking, the solution absorbance was measured at 570 nm with the use of
Fluoroscan Ascent microplate reader (Thermo Fisher Scientific Inc., Waltham, MA, USA). The relative
cell viability (%) was calculated as following:
Cell viability = (Asample – Ablanck)/ (Acontrol – Ablanck) × 100% (2)
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2.2.5. Cellular Uptake
To visualize cell penetration of nanoparticles loaded with siRNA we used polypeptide particles
loaded with Cy5 labeled VEGF siRNA. Approximately 10,000 ARPE-19 cells were seeded per well in a
96-well plate (Thermo ScientificTM NuncTM MicroWellTM) in DMEM-F12. After 12 h, the medium was
removed by aspiration and 90 µL serum-free DMEM-F12 medium with penicillin and streptomycin
was added to each well. Peptide nanoparticles loaded with siRNA were added to cells (concentration
of Cy-5 labeled siRNA was 1 nmol/mL). The cells were incubated with particles at 37 ◦C in serum-free
medium for 4 h. Then the cells were washed with 1 M sodium chloride to remove remaining extra
particles from cell surface, and the wells were filled with DMEM-F12 and the incubation continued for
44 h more. In each well the cells were fixed using 200 µL of 3.7% solution of formaldehyde in methanol.
After that, the cells were washed three times with PBS.
We used Permeabilization Buffer (0.2% Triton X-100 in PBS) to permeabilize cell membranes.
Cell nuclei were stained with Hoechst 33,258 (1 µg/mL) for 30 min according to the protocol published
elsewhere [28]. After that, the cells were washed for three times with PBS and two times with water in
order to remove crystals of salt.
The cell membranes were stained by CellMask Green Plasma Membrane Stain (Thermo Fischer
Scientific, Paisley, UK), according to the manufacturer’s protocol. The study of cellular uptake was
performed using CELENA S Digital Imaging System (Logos Biosystems, GE Healthcare, Anyang,
Korea) and Cytell Cell Imaging instrument (GE Healthcare, Issaquah, WA, USA) by analysis of the
fluorescence intensity of Cy5-siRNA.
To confirm particle penetration into the cells, we performed an additional experiment. For this
purpose, we labeled polypeptide particles with Cy5 and used Cy3-oligo-dT-dA for encapsulation.
10 µL of 0.1 mg/mL solution of Cy5 in DMSO was added to 500 µL of 0.1 mg/mL suspension of
nanoparticles in 0.01 M Na-phosphate buffer, pH 7.4, and stained for 1 h at 37 ◦C. Non-bound Cy5
was separated from nanoparticles by centrifugation (10,000× g) using filter tubes with MWCO 10,000
(Merck, Darmstadt, Germany) 7–8 times until the filtrate was free from Cy5. The encapsulation of
Cy3-dT-dA and the cell experiments were the same as described above.
2.2.6. VEGF Gene Silencing
The efficacy of siRNA, loaded in peptide nanoparticles, against VEGF was evaluated in ARPE-19
cells. Approximately 4× 104 ARPE-19 cells were seeded per well in a 24-well plate (Thermo ScientificTM
NuncTM MicroWellTM) in DMEM-F12/10% FBS (Biowest, Nuaille, France)/50 IU/mL penicillin/50 µg/mL
streptomycin (BioloT) overnight. After that, the medium was removed by aspiration and 500 µL
serum-free DMEM-F12 medium was added to each well. Then, 0.05 nmol of the siRNA loaded in
33.5 µg of polypeptide particles was added to each well (mass ratio particles:siRNA was equal to
4:1). The siRNA concentration was 100 nM and it was selected from data published elsewhere for
ARPE-19 cells where the concentration range from 10 to 1000 nM was investigated [29,30]. The cells
were incubated with particles at 37 ◦C for 4 h. Then the medium was replaced with fresh one and the
incubation continued additionally for 44 h. To investigate RNA interference in the absence of VEGF we
used the nanoparticles with scrambled siControl. The conditions were the same as for target siRNA.
2.2.7. Total RNA Isolation, Reverse Transcription and Quantitative Real-Time PCR Analysis
The efficiency of VEGF silencing was estimated by measuring VEGF mRNA expression
quantitatively using real-time reverse transcription polymerase chain reaction (RT-PCR).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression level was used as a
housekeeping gene. After lysis of ARPE-19 cells, the total RNA was isolated using an RNA extraction
kit from Biosilica (Novosibirsk, Russia) according to the manufacturer’s instructions and the RNA
concentration was measured by the absorbance at 260 nm wavelength using an UV NanoDrop
spectrometer (Thermo Scientific, Rockford, IL, USA). The ratio of absorbance at 260 nm and 280 nm for
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noncontaminated RNA samples was in the range of >1.8 and <2.2 [31]. The integrity of total RNA was
determined by native 1% agarose gel electrophoresis [31]. Intact 28S and 18S rRNA were detected
on a gel as sharp bands with intensity ratio ~2:1 and no signs of genomic DNA contaminations were
observed. Then, 60 ng of cDNA was synthesized using the MMLV RT kit (Evrogen, Moscow, Russia).
After that, 12 ng of cDNA was applied for RT-PCR with the respective VEGF forward, VEGF reverse,
GADPH forward, and GADPH reverse primers. RT-PCR was performed using a qPCRmix-HS SYBR
(Evrogen) according to the manufacturer’s instruction. The PCR performed for 40 amplification cycles
of 95 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for 45 s. The amount of VEGF mRNA was determined
relative to the amount of housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA in the same sample by the equation X0/R0 = 2CtR−CtX, where X0 is the original amount of
VEGF mRNA, R0 is the original amount of GAPDH mRNA, CtR is the Ct (cycle threshold) value for
GAPDH, and CtX is the Ct value for VEGF.
2.2.8. Western Blotting
To confirm the results of VEGF-silencing on protein level, western-blotting was performed as well.
ARPE-19 cells were seeded on 6-well plate at a density of 8 × 105 cells/well in DMEM-F12. After 12 h,
the medium was aspirated, and 2 mL serum-free DMEM-F12 medium with penicillin and streptomycin
was added. Then, 0.8 nmol of the siRNA loaded in polypeptide nanoparticles was added (mass ratio
polymer:siRNA was 4:1). The nanoparticles with scrambled siRNA sequence were used as a control.
For analysis of VEGF level suppression in a presence of nanoparticles loaded with siRNA, ARPE-19
cells were cultured for 5 days (instead of 2 days as for mRNA study) due to the slow turnover of
the protein [13,32]. Afterwards, the cells were lysed with radioimmunoprecipitation assay (RIPA)
buffer. Total protein in the lysate was quantified by Bradford assay using the albumin calibration
curve as a standard. The equal amount of protein (20 µg) was separated on a 12% SDS-PAGE gel and
electroblotted onto polyvinylidenedifluoride (PVDF) membrane (0.2 µm, Thermo Scientific, Rockford,
IL, USA) at 400 mA for 20 min. The PVDF membrane was blocked with 5% (w/v) nonfat dried milk
diluted in TBS buffer with 0.1% (v/v) Tween 20 for 1 h at room temperature. Recombinant humanized
monoclonal anti-(human VEGF) antibody (1:20,000; Avastin, Roche, Welwyn Garden City, UK) and
monoclonal mouse anti-(human β-actin) antibody (1:1000) (Santa Cruz Biotechnology, Heidelberg,
Germany) were used as primary antibodies and horseradish peroxidase-linked rabbit anti-human IgG
Fc antibody (1:10,000; Thermo Fisher Scientific) and rabbit anti-goat IgG (H + L) antibody (1:10,000;
Thermo Fisher Scientific) were used as secondary antibodies. Blots were developed with enhanced
chemiluminescence Amersham Hyperfilm ECL reagent and detection was done using Amersham
Imager 600 Instrument (GE Healthcare, Little Chalfont, UK).
2.2.9. Statistical Analysis
To analyze the statistical significance among the groups, one-way analysis of variants (ANOVA)
in Excel with the XLSTAT was used. Data were expressed as mean ± SD (n = 3). p ≤ 0.05 was counted
as a statistically significant.
3. Results and Discussion
3.1. Synthesis and Characterization of Polypeptides
Two series of polypeptides with different hydrophobic amino acid contents were synthesized by
varying the initial ratio of amino acids in the synthesis. Polypeptides had a random primary structure
that was generated during copolymerization of NCAs of l-Lys(Z), l-Glu(OBzl) and l-Phe/l-Ile via
ROP technique [33]. Weight average molecular weight (Mw), number average molecular weight (Mn)
and dispersity (Ð) of protected copolymers were evaluated using size-exclusion chromatography
(SEC) in DMF with refractometric detection regarding poly(methyl methacrylate) standards (Table 1).
Additionally, for some samples Mw values were also determined by static light scattering (SLS) (Table 1
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and Supplementary Materials Table S1) to testify the applicability of used SEC for such kind of polymers.
Mw values measured by both methods were found to be close. The polydispersity of the samples was
in the range of 1.10–1.33 that corresponds to quite narrow molecular weight distribution.
Table 1. Molecular-weight characteristics of protected polypeptides determined by SEC and SLS.
Sample
Polymer Characteristics
SEC SLS
Mn Mw Ð Mw
P(Lys(Z)n-co-Glu(OBzl)m-co-Phek)
KEF1 20,170 23,600 1.17 23,000
KEF2 9400 17,000 1.80 17,500
KEF3 10,000 13,200 1.32 17,400
P(Lys(Z)n-co-Glu(OBzl)m-co-Ilek)
KEI1 21,350 28,400 1.33 18,800
KEI2 16,090 21,240 1.32 17,100
KEI3 17,560 22,300 1.27 -
The amphiphilic copolymers were prepared via deprotection of ε-amino groups of lysine and
γ-carboxylic groups of glutamic acid. After deprotection, the copolymers acquired the tendency to
self-assembly in aqueous media. The completeness of removal of the protective groups was verified by
1HNMR spectroscopy (Supplementary Materials Figure S1).
HPLC analysis of hydrolyzed polypeptide samples allowed for the determination of the ratio
between amino acids (Table 2). The samples KEF1, KEF2, and KEI1-KEI3 were enriched with lysine
whereas KEF3 was enriched with glutamic acid. Additionally, to evaluate polymer composition,
the samples were analyzed by 1H-NMR spectroscopy. 1HNMR spectra and information on correlations
of signals can be found in Supplementary Materials (Figures S2 and S3). For both Phe- and Ile-containing
copolymers, the content of hydrophilic (Lys + Glu) and hydrophobic (Phe or Ile) amino acids (mol%)
established by HPLC amino acid analysis was in an agreement with data obtained by 1HNMR
spectroscopy. Due to the overlap of signals related to the carboxybenzyl and benzyl groups of
Lys(Z) and Glu(OBzl), the separate calculation of Lys and Glu content could not be possible by
1HNMR method.
Table 2. Composition of amphiphilic amino acid polypeptides.
Sample
Determined Polymer Composition (mol%)
HPLC 1HNMR
Lys Glu Phe/Ile Lys + Glu Phe/Ile
P(Lysn-co-Glum-co-Phek)
KEF1 55 25 20 76 24
KEF2 75 9 16 75 25
KEF3 21 54 25 64 36
P(Lysn-co-Glum-co-Ilek)
KEI1 66 16 18 85 15
KEI2 57 31 12 88 12
KEI3 54 36 10 - -
3.2. Preparation and Characterization of Polypeptide Particles
The preparation of nanoparticles (NPs) based on the synthesized polypeptides was carried out
by gradient solvent inversion approach favoring to slow polymer self-assembly and followed by
freeze-drying. Before application, the necessary amount of sample was redispersed in water or
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0.01 M PBS via short-term ultrasonic exposure (30 s). Usually, the main force for the self-assembly
of amphiphilic polymers is the interactions between hydrophobic regions of macromolecules in
organic-aqueous or aqueous media to reduce the area of contact with water. At the same time,
the hydrophilic fragments are exposed into aqueous medium because of their good solvation with
water. In our amphiphilic macromolecules, except hydrophobic interactions, the electrostatic forces
play a role due to the presence in polypeptides positively charged Lys and negatively charged Glu
residues. Such complex interactions between polypeptide chains should provide high stability of
self-assembled nanoparticles.
Size, surface charge and stability are among the most important parameters of nanoparticles,
affecting cellular uptake and cytotoxicity. Various methods were used in this study to characterize the
polypeptide nanoparticles obtained. Such parameters as hydrodynamic diameter (DH), polydispersity
index (PDI) and electrokinetic potential (ζ-potential) of obtained nanoparticles were determined by
dynamic light scattering (DLS) and electrophoretic light scattering, respectively (Table 3). The smallest
particles with the average hydrodynamic diameter about 200 nm were formed when Lys/Glu ratio
ranged from 1.9 to 2.8 (samples KEF1, KEI1 and KEI2). The same samples were also characterized
with the lowest PDI. As expected from the copolymer’s composition, all samples, except KEF3,
had positive ζ-potential, while KEF3 sample, enriched with glutamic acid (Table 2), was charged
negatively. We chose the samples KEF1, KEI1 and KEI2 for further studies.
Table 3. Characteristics of polypeptide nanoparticles obtained (DLS, in 0.01 PBS, pH 7.4).
Sample Particle Characteristics
DH, nm PDI ζ-Potential, mV
P(Lysn-co-Glum-co-Phek)
KEF1 200 ± 8 0.22 +12 ± 2
KEF2 550 ± 14 0.31 +18 ± 5
KEF3 900 ± 38 0.39 −6 ± 3
P(Lysn-co-Glum-co-Ilek)
KEI1 232 ± 11 0.14 +49 ± 2
KEI2 180 ± 19 0.19 +45 ± 3
KEI3 440 ± 31 0.30 +31 ± 5
The critical micelle concentration (CMC) were determined for the selected polymers
by conductometry method [34]. With increasing polymer concentration, the formation of
thermodynamically stable aggregates starts and it is can be detected as a change in solution conductivity.
The CMC values were calculated by a linear fitting of the two data subsets and calculating the
concentration at their intersection (Supplementary Materials Figure S4). CMC values for KEF1, KEI1
and KEI2 were found to be close to each other and equal to 8.9, 10.6 and 6.2 mg/L, respectively.
The values determined were close [35] or even lower [36] than these established for other amphiphilic
random copolymers.
Polypeptide nanoparticles were studied with nanoparticle tracking analysis (NTA) and
transmission electron microscopy (TEM) to receive more information about their size, shape and
structure. As an example, Figure 1 illustrates TEM and NTA images obtained for sample KEI2.
According to TEM investigations, the nanoparticles of chosen sample represented spheres with a mean
diameter of about 160 ± 50 nm. NTA allows for the determination of hydrodynamic diameter and size
distribution profile of small particles that are hard to capture by DLS. According to NTA, there were
three modes of nanoparticles with DH around 130, 180 and 240 nm. In turn, the DLS measurements
gave the average value for the same sample equal to 180 nm with no detection of particles of different
size (Supplementary Materials Figure S5). Similar results were obtained for two other selected samples
(KEF1 and KEI1).
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increase of encapsulated duplex oligo-dT-dA (Figure 3). A significant aggregation was observed 
when the polymer:oligonucleotide ratio reached 2:1 and the surface charge dropped to +8 mV. Thus, 
it can be deduced that polymer:oligonucleotide ratio 4:1 provided the smallest particles with a 
noticeable surface charge. 
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until the polymer:oligo-dT-dA ratio reached 2:1, the oligonucleotide encapsulation was carried out 
Figure 1. Size and structure of polypeptide nanoparticles (sample KEI2), investigated by TEM (A) and
NTA (B).
The pH of solutions did not affect the particle size until it reached 10.5 (Figure 2A). At this
point, ε-amino groups of lysine are deprotonated and became neutrally charged. As a result,
an aggregation takes place. Such behavior was observed previously for random copolymers of lysine
and phenylalanine [37]. In that case, the 10-fold increase in DH was detected. For terpolymers
containing two oppositely charged amino acids (lysine and glutamic acid), the hydrodynamic diameter
of the particles also increased but not so drastic: Only two-fold growth of DH was registered.
Moreover, further pH elevation to 11 and 12 followed with charge switching to negative, −17 and
−36 mV, respectively. The negative charge is explained by deprotonating of γ-carboxylic groups of
glutamic acid, while amino group of lysine was uncharged. Moreover, the hydrodynamic diameter of
nanoparticles at pH 12 returned to the initial value.
The stability of nanoparticles was studied in PBS and DMEM over 7 days. All samples proved to
be colloidally stable, keeping their size and surface charge constant (Figure 2B).
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3.3. Entrapment and Release of Duplex Oligo-dT-dA
Entrapment efficacy and release kinetics are crucial characteristics for developed delivery
system. At first, it was important to understand how the loading of oligonucleotide influences
the physico-chemical characteristics of nanoparticles. For this purpose, duplex oligo-dT-dA was used
as the cheaper and stable model of siRNA. The positively charged nanoparticles (sample KEI2) were
loaded with negatively charged oligo-dT-dA due to polyelectrolyte interactions. The hydrodynamic
diameter of the loaded particles as well as the surface charge depended on polymer:oligonucleotide ratio,
while mean PDI was constant and equal to 0.18±0.01. The particle’s hydrodynamic diameter decreased
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gradually and the surface charge lowered steadily with the increase of encapsulated duplex oligo-dT-dA
(Figure 3). A significant aggregation was observed when the polymer:oligonucleotide ratio reached 2:1
and the surface charge dropped to +8 mV. Thus, it can be deduced that polymer:oligonucleotide ratio
4:1 provided the smallest particles with a noticeable surface charge.
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formulation. At the same time, the release in DMEM without serum was negligible. The release in 
DMEM-F12 + FCS medium is explained by the presence of different negatively charged components 
like proteins and vitamins at relatively high concentrations that could interact with polypeptide 
and, therefore, gradually replace oligonucleotide. Since there are a lot of proteins and other 
molecules with negative charge in the cytoplasm, we suppose that this mechanism of substitution 
will work also inside a cell to release siRNA. 
Figure 3. Hydrodynamic diameter (A) and surface charge (B) of olypeptide nanoparticles
(sample KEI2), loade with duplex oligo-dT-dA.
To compare the entrapment efficacy and to study the oligonucleotide release kinetics, we used the
same oligonucleotide but labeled with Cy3 fluorescent dye. Since the particle size was stable until
the polymer:oligo-dT-dA ratio reached 2:1, the oligonucleotide encapsulation was carried out in the
range of this ratio from 4:1 to 20:1. Since pH does not affect particle size and morphology (except at
pH 10.5) the encapsulation was performed in pure water. Almost 100% of labeled oligonucleotide
was entrapped into polypeptide nanoparticles, regardless polymer:oligonucleotide ratio (Figure 4A).
Therefore, the ratio 4:1 was appeared to be suitable for further experiments.
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Figure 4. Entrapment efficacy (A) and release (B) of duplex oligo-dT-dA (sample KEI2) from the
complex (polymer:oligo-dT-dA ratio equal to 4:1).
The release of duplex oligo-dT-dA was studied for the system obtained at polymer:oligo-dT-dA
ratio = 4:1. A simple buffer sy t m (PBS, pH 7.4), a complex medium containing amino acids, vitami s
and inorganic salts (DMEM) nd DMEM-F12 containi g 10% of fetal calf serum (DMEM-F12 + FCS)
were used as the media for experiments. About 50% of oligonucleotide duplex was eleased over 24 h
in DMEM-F12 + FCS (Figure 4B). After 5 days of incubation in DMEM-F12 + FCS at 37 ◦C, the release
reached 95%. Howev r, oligonucl otide duplex did not escape polymer particles in PBS during 5 days
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that means good storage stability of formulation. At the same time, the release in DMEM without
serum was negligible. The release in DMEM-F12 + FCS medium is explained by the presence of
different negatively charged components like proteins and vitamins at relatively high concentrations
that could interact with polypeptide and, therefore, gradually replace oligonucleotide. Since there
are a lot of proteins and other molecules with negative charge in the cytoplasm, we suppose that this
mechanism of substitution will work also inside a cell to release siRNA.
Additionally, we prepared the polyplex of poly-L-lysine and duplex oligo-dT-dA in the same ratio
(4:1) and studied the release of oligonucleotide in DMEM and DMEM-F12 + FCS over 5 days (37 ◦C).
It was established that the oligo-dT-dA release in DMEM did not exceed 2.5%. The presence of FCS
in medium slightly facilitated the release of target compound, however, even in this case it did not
exceed 8% (Supplementary Materials Figure S6). Thus, the combination of positively and negatively
charged amino acids, e.g., lysine and glutamic acid, indeed facilitate the release of oligonucleotides in
comparison with poly-L-lysine.
3.4. Cytotoxicity
Since the stability of nanoparticles for 7 days in the test medium was proven with DLS,
we proceeded the investigation of their cytotoxicity in cultured cells (Figure 5 and Supplementary
Materials Figure S7). For this purpose, MTT assay was performed using three cell lines, e.g., HEK-293,
BEAS-2B and ARPE-19 cells. The cells were incubated in the presence of polypeptide nanoparticles
(KEF1, KEI1, KEI2) for 72 h. It was established that the samples KEF1 and KEI2 were not toxic for
HEK-293 and BEAS-2B cells in the concentration range of 4–125 µg/mL. For the sample KEI1, modest
cytotoxicity was observed at concentration 125 µg/mL (viability 65 ± 1%). In the case of ARPE-19,
cell viability was higher than 75% for KEI1 and KEI2 samples in the whole tested concentration range.
The sample KEF1 demonstrated evident cytotoxicity at the concentration of 125 µg/mL.
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3.5. VEGF Gene Silencing
To investigate VEGF gene silencing, KEF1, KEI1 and KEI2 nanoparticles were selected as the
delivery systems for anti-VEGF siRNA. We used ARPE-19 cells that express VEGF constitutively.
The experiment was carried out using the polymer:siRNA mass ratio of 4:1; the concentration of
polymer particles used for experiment was 67 µg/mL. RNA interference of anti-VEGF siRNA was
analyzed by RT-PCR.
All investigated samples demonstrated strong inhibitory effect on mRNA expression (Figure 6).
The minimal inhibitory effect of 60% was reached, using KEF1 as a delivery system, while KEI1 and
KEI2 inhibited VEGF gene expression more effectively (p < 0.01) (Figure 6). In particular, VEGF
silencing reached with the use of KEI1 and KEI2 siRNA delivery systems corresponded to 82 and
71%. For comparison, 40–70% GFP gene knockdown was reported by Zhu et al. for the application of
poly(dimethylaminoethyl methacrylate)-b-polycaprolactone-b-poly(dimethylaminoethyl methacrylate)
systems for delivery of siRNA [38]. Wei et al. reported the application of chitosan-based systems for
delivery of mTERT siRNA. The reached gene silencing was equal to 56% [39]. As to VEGF knockdown,
the delivery systems based on poly(ε-caprolactone)- polyethyleneglycol-poly(l-histidine) provided up
to 55% VEGF gene silencing in MCF-7 and HUVEC cells (siRNA concentration and incubation time with
cells were 100 nM and 5 days, respectively) [13]. Thus, the polypeptide systems, developed in present
work, can be considered as efficient for intracellular siRNA delivery and VEGF gene knockdown.
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Fluorescence microscopy images of ARPE-19 cells treated with Cy5-siRNA–polypeptide particles
showed effective cell penetration of Cy5-labeled siRNA. Most siRNAs were located in the cytoplasm
(Figure 6). According to the fluorescent images, the delivery of Cy5-labled siRNA with KEI1
nanoparticles followed with much more pronounced aggregation of NPs. Taking this into account
Pharmaceutics 2020, 12, 39 14 of 17
as well as gene silencing results and the data on cytotoxicity, KEI2 sample was selected for further
western blotting analysis.
To verify the suppression of VEGF expression due to the gene silencing the western blotting was
carried out. For this, KEI2 nanoparticles loaded with siRNA was used as sample whereas scrambled
siRNA loaded in the same kind of NPs was applied as negative control. Additionally, empty NPs were
also applied as control to reveal if they can influence on the process under study. According to the
results obtained, the expression of VEGF under siRNA delivery system application was suppressed
approximately by 60% (p < 0.03) (Figure 7). The results obtained are in a good agreement with data
on RNA interference evaluated by RT-PCR where the same sample provided gene silencing by 70%.
No suppressing effect was detected for both empty NPs and scrambled siControl-NPs.
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Figure 7. VEGF protein expression in the ARPE-19 cells determined by western blotting (KEI2 NPs).
4. Conclusions
In this study, polymers based on lysine, glutamic acid and phenylalanine/isoleucine were
developed for the delivery of oligonucleotides. The polymers self-assembled into spherical particles
with av rage hydrodynamic diameters f 180–900 nm that w re colloidally stable in PBS and c ll
culture medium (DMEM). The mod l duplex of oligonucleotid s (oligo-dT-dA) was encapsulat d
in he polymer nanoparticles up to 4:1 mass ratio (polymer:oligo-dT-dA) without a y size change
in nanoparticles. The interaction between olig nucleotide duplex and the p lymer was strong and
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components like proteins, vitamins an amino acids in DMEM-F12 + FCS enhanced the release an
56% of oligonucleotide was freed over 48 h. The cell viability test demo strat t e absence of
cytot xicity for th sample KEI2 for three cell lines whereas for some other samples slight toxic effect
was detected. T efficient VEGF gene silencing was established at the applic tion of developed
polypeptide nanoparticles as siRNA delivery systems.
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with poly-l-lysine:oligonucleotide (ratio 4:1), Figure S7: Nanoparticle’s cytotoxicity in BEAS-2B and HEK-293 (a–c)
and ARPE-19 cells (d) (24 h): (a) sample KEF1, (b) sample KEI1, (c) sample KEI2 and (d) sample KEI2, Table S1:
Data of static (SLS) and dynamic (DLS) light scattering of polymer solutions (DMSO).
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